

**Salivary Soluble CD44 As A potential
Molecular Marker for
Oral cancer**

Thesis

Submitted in the Partial Fulfillment for the
Requirement of the Doctorate Degree in Oral Medicine
And Periodontology

Presented by

Dalia Mohey El Deen Ghalwash

B.Ch.D (Alexandria University)

M.D.S. (Cairo University)

Oral Medicine and Periodontology Department

Faculty of Oral and Dental Medicine

Cairo University

2009

Abstract

One candidate molecular marker for oral cancer is CD44. The present study was carried out on 40 subjects. Levels of salivary sCD44 among patients with: oral cancer, premalignant lesions with & without dysplasia and controls were measured using an ELISA assay. The results of the present study indicate that a level of salivary sCD44 lying within the range of 19.2 to 20.4 ng/ml could indicate malignant transformation. The significant increase in CD44 level in oral cancer patients makes it a potential molecular marker for oral cancer.

Keywords:

Cancer, molecular marker, CD44, premalignant, dysplasia.

LIST OF TABLES

Table number	Heading	Page
<i>1</i>	Criteria Used for Diagnosing Epithelial Dysplasia (Pindborg <i>et al.</i> , 1997)	<i>6</i>
<i>2</i>	Potential mechanisms for the generation and function of cell surface, matrix-associated, and fluid phase CD44.	<i>18</i>
<i>3</i>	Saliva components and functions (Llena-Puy, 2006)	<i>47</i>
<i>4</i>	Classification schemas that histologically categorize precursor and related lesions (Gale <i>et al.</i> , 2005).	<i>64</i>
<i>5</i>	Age, gender, clinical diagnosis, smoking status and salivary sCD44 level of all included subjects.	<i>78</i>
<i>6</i>	Cases with malignant lesions, their clinical grading and their salivary sCD44 level.	<i>79</i>
<i>7</i>	Comparison between control and premalignant without dysplasia groups according to salivary sCD44 level.	<i>84</i>
<i>8</i>	Comparison between control and premalignant with dysplasia groups according to salivary sCD44 level.	<i>84</i>
<i>9</i>	Comparison between control and cancer groups according to salivary sCD44 level.	<i>86</i>
<i>10</i>	Comparison between premalignant without dysplasia and premalignant with dysplasia groups according to salivary sCD44 level.	<i>86</i>
<i>11</i>	Comparison between premalignant without dysplasia and cancer groups according to salivary sCD 44 level.	<i>87</i>
<i>12</i>	Comparison between premalignant with dysplasia and cancer groups according to salivary sCD44 level.	<i>87</i>
<i>13</i>	Correlation between the salivary sCD 44 and sex.	<i>91</i>
<i>14</i>	Correlation between the CD 44 and Smoking.	<i>93</i>
<i>15</i>	Correlation between age and salivary sCD 44 in the different studied groups.	<i>95</i>

LIST OF FIGURES

Figure number	Heading	Page
1	Model for the structure of CD44.	16
2	The genomic structure of CD44 (top) with examples of potential isoforms of CD44. TM, transmembrane.	16
3	Proteolytic processing of CD44.	21
4	CD44 exists in three phases: a typical transmembrane receptor, a matrix-associated fragment of the extracellular domain, and as soluble fragments in the fluid phase.	24
5	Clinical photograph showing a case with smoker's keratosis (male, age: 44, heavy smoker 20 cigarette/day for 20 years).	56
6	Clinical photograph showing another case with smoker's keratosis (male, age: 65, heavy smoker 30-40 cigarette/day for 30 years).	56
7	Clinical photograph showing another case with smoker's keratosis on the left cheek (male, age: 46 years, heavy smoker 20 cigarette/day for 25 years).	57
8	Same case as shown in figure (7). The photograph shows the right cheek.	57
9	Clinical photograph showing a case suffering from speckled leukoplakia (male, age: 46 years, smoker).	58
10	Clinical photograph showing another case suffering from speckled leukoplakia (male, age: 45 years).	58
11	Clinical photograph showing a case of leukoplakia on the lateral boarder of the tongue (female, age: 35 years).	59
12	Clinical photograph showing a case of oral lichen planus; atrophic and reticular patterns (female, age: 45 years).	59
13	Clinical photograph showing another case of oral lichen planus; plaque and atrophic patterns (female, age: 55 years).	60
14	Clinical photograph showing another case of oral lichen planus; atrophic and reticular patterns (male, age: 60 years).	60
15	Clinical photograph showing a case of squamous cell carcinoma at the junction between ventral surface of the tongue and the floor of the mouth (female, age: 50 years).	61

16-a	Photomicrograph of H&E stained biopsy specimen of a leukoplakia case showing mild dysplastic changes (SIN1)	65
16-b	Photomicrograph of H&E stained biopsy specimen of a case of speckled leukoplakia showing mild dysplastic changes (SIN1)	65
17	Photomicrograph of H&E stained biopsy specimen of one of the included lichen planus cases showing moderate dysplastic changes (SIN2)..	67
18(a-b)	Photomicrograph of H&E stained biopsy specimen of another one of the included lichen planus cases (a: x100; b: x400) showing severe dysplastic changes (SIN3).	67
19	ELISA steps.	69
20	A photograph showing the centrifuge.	69
21	Principles of the Test	71
22	ELISA reader.	71
23-a,b,c	The figure shows the constituents of human salivary sCD44std ELISA kit for quantitative detection of human salivary sCD44std.	73
24	Distribution of the control group according to sex.	80
25	Distribution of the premalignant without dysplasia group according to sex.	80
26	Distribution of the premalignant with dysplasia group according to sex.	81
27	Distribution of the cancer group according to sex.	81
28	Comparison between the two studied groups according to sex.	82
29	Comparison between the studied groups according to age	82
30	Comparison between the studied groups according to salivary sCD44 levels.	89
31	Correlation between salivary sCD44 level and sex.	91
32	Correlation between salivary sCD44 level and smoking.	93
33	Correlation between age and salivary sCD44 in the cancer group.	95
34	Distribution chart for salivary sCD44 level of the 40 cases.	97
35	ROC curve; considering the 4 groups (the first three groups as control)	99
36	ROC curve; considering the 2 groups, control and cancer.	99

INTRODUCTION

Oral cancers annually strike hundreds of thousands around the globe. Despite treatment advances, the disease's overall five-year survival rate has not improved in the past three decades and remains among the worst of all cancers. One factor behind oral cancer's high mortality is the difficulty of detecting it at its early stages (**Wong, 2006; Prince et al., 2007**).

Invasive oral squamous cell carcinoma is often preceded by the presence of clinically identifiable premalignant changes of the oral mucosa. Identification of high-risk oral premalignant lesions and intervention at premalignant stages could constitute one of the keys to reducing the mortality, morbidity and cost of treatment associated with OSCC (**Neville and Day, 2002**).

The last three decades have witnessed a rapid advancement and diffusion of technology in health services. Technological innovations have given health service providers the means to diagnose and treat an increasing number of illnesses, including cancer. In this effort, research on biomarkers for cancer detection and risk assessment has taken a center stage in the effort to reduce cancer deaths. For the first time, scientists have the technologies to decipher and understand these biomarkers and to apply them to earlier cancer detection. By identifying people at high risk of developing cancer, it would be possible to develop intervention efforts on prevention rather than treatment. Once fully developed and validated, then the regular clinical use of biomarkers in early detection and risk assessment will

meet nationally recognized health care needs: detection of cancer at its earliest stage (**Verma et al., 2001**).

One candidate molecular marker for HNSCC is CD44 which is one of the adhesion molecules. CD44 proteins are also released in soluble form (sCD44) via proteases and are detectable in normal circulation. Circulating levels of sCD44 correlate with metastases in some tumors (**O'Hara and Bradley, 2002**).

Actually, increased levels of sCD44 were not only reported in head & neck cancer, but also it was reported to be increased in colorectal cancer, gastric carcinoma, renal cancer, primary breast cancer and non-Hodgkin's lymphoma (NHL) (**Harn et al., 1996; Kan et al., 1996; Masson et al., 1999; Niitsu and Iijima, 2002; Mayer et al., 2008**). These authors came out with the conclusion that sCD44 could be considered as a marker in all these types of cancer.

Technological advances over the past decades have enabled oral fluid to expand its usefulness in the diagnosis of disease, prediction of disease progression, monitoring of therapeutic drug levels and detection of illicit drugs. The easy non-invasive nature of collection and the relationship between oral fluid and plasma levels make oral fluid a valuable clinical tool (**Choo and Huestis, 2004**).

Franzmann et al. (2005, 2007) reported correlation between high level of salivary sCD44 and malignant transformation in oral lesions. Consequently, it became a tempting issue for research.

بسم الله الرحمن الرحيم

„علم الانسان ما لم يعلم“

صدق الله العظيم

سورة العلق آية "٥"

Achnoledgment

First and foremost, I would like to express my greatest thankfulness to **Allah** the most merciful, who created man and gave him the knowledge to think, believe, and worship.

I would like to express my deepest gratitude and appreciation to **Professor Dr. Khaled El-Gaaly** Professor of Oral Medicine Oral Diagnosis and Periodontology, Faculty of Oral and Dental Medicine, Cairo University, for his close supervision, valuable contribution with knowledgement and advice during the course of this study. Without his support, this work would not have reached its final stages.


My great thanks and appreciation go to **Professor Dr. Fatheya Zahran**, Professor of Oral Medicine Oral Diagnosis and Periodontology, Faculty of Oral and Dental Medicine, Cairo University; for her precise supervision, her meticulous observation, her continuous encouragement, and for giving me generously of her time.

My gratitude and thanks to **Professor Dr. Olfat Shaker**, Professor of Biochemistry, Faculty of Medicine, Cairo University, for her sincere help, valuable contributions, and her valuable scientific guidance.

I would like also to express my sincere appreciation and gratitude to **Professor Dr. Mahmoud El Refaay**, Professor and Chairman of Oral Medicine and Periodontology Department, Faculty of Oral and Dental Medicine, Cairo University, for his sincere help, advise and support.

My gratitude and thanks to all staff members of the Oral Medicine and Periodontology Department Faculty of Oral and Dental Medicine, Cairo University, for their sincere support and cooperation.

Special thanks to **Dr. Hosam Abd El Kader El-Foll**, Lecturer of Surgical Oncology, Faculty of Medicine, Monofeya University; for his valuable contributions during the course of this study.



Dedication

To my Family,

My parents,

My husband,

And my sweethearts, Mariam & Mostafa.

CONTENTS

<i>(I) Introduction</i>	<i>(1-2)</i>
<i>(II) Review of literature</i>	<i>(3-52)</i>
<i>(III) Aim of the study</i>	<i>(53)</i>
<i>(IV) Subjects and Methods</i>	<i>(54-75)</i>
<i>(V) Results</i>	<i>(76-100)</i>
<i>(VI) Discussion</i>	<i>(101-116)</i>
<i>(VII) Conclusion & Recommendations</i>	<i>(117)</i>
<i>(VIII) Summary</i>	<i>(118-120)</i>
<i>(IX) References</i>	<i>(121-152)</i>
<i>(X) Arabic summary</i>	

Supervisors

Professor Dr. Khaled El-Gaaly

Professor of Oral Medicine
Oral Diagnosis and Periodontology, Faculty of
Oral and Dental Medicine
Cairo University

Professor Dr. Fatheya Zahran

Professor of Oral Medicine
Oral Diagnosis and Periodontology, Faculty of
Oral and Dental Medicine
Cairo University

Professor Dr. Olfat Shaker

Professor of Biochemistry
Faculty of Medicine
Cairo University

AIM OF THE STUDY

This study was carried out in order to determine the validity of sCD44 ELISA test on saliva and its effectiveness in detecting oral cancer and possibly early malignant transformations in some premalignant lesions.

REVIEW OF LITERATURE

Head and neck squamous cell carcinoma (HNSCC) accounts for more than 95% of all head and neck malignancies. Unfortunately, the majority of HNSCC patients present with advanced stage disease, requiring multimodality therapy. Even with combinations of intensive chemotherapy, radiotherapy, and surgery, cure rates are only 30% for advanced stage disease. Those cured often face serious morbidities including speech and swallowing problems, disfigurement, and exorbitant healthcare costs (*Franzmann et al., 2005; Mehrotra and Yadav, 2006*).

Early oral cancers and precancerous lesions are often subtle and asymptomatic. Therefore, it is important for the clinician to maintain a high index of suspicion, especially if risk factors such as tobacco use or alcohol abuse are present. A key factor in the lack of improvement in prognosis over the years is the fact that a significant proportion of oral squamous cell carcinoma (OSCC) are not diagnosed or treated until they reach an advanced stage. This diagnostic delay may be caused by either patients (who may not report unusual oral features) or by health care workers (who may not investigate observed lesions thoroughly) and it is presumed that such delays are longer for asymptomatic lesions. The prognosis for patients with OSCC that is treated early is much better, with 5-year survival rates as high as 80%. In addition, the quality of life improves after early treatment, because cure can be achieved with less